Literature DB >> 35066510

Functional Transcriptomic Studies of Immune Responses and Endotoxin Tolerance in Early Human Sepsis.

Aleksandra Leligdowicz1,2, Jack Kamm3, Katrina Kalantar4, Alejandra Jauregui1, Kathryn Vessel1, Saharai Caldera3, Paula Hayakawa Serpa3,5, Jason Abbott1, Xiaohui Fang1, Xiaoli Tian6, Arun Prakash6, Kirsten Neudoerffer Kangelaris7, Kathleen D Liu1,8, Carolyn S Calfee1,8, Charles Langelier3,5, Michael A Matthay1,8.   

Abstract

BACKGROUND: Limited studies have functionally evaluated the heterogeneity in early ex vivo immune responses during sepsis. Our aim was to characterize early sepsis ex vivo functional immune response heterogeneity by studying whole blood endotoxin responses and derive a transcriptional metric of ex vivo endotoxin response.
METHODS: Blood collected within 24 h of hospital presentation from 40 septic patients was divided into two fractions and incubated with media (unstimulated) or endotoxin. Supernatants and cells were isolated, and responses measured using: supernatant cytokines, lung endothelial permeability after supernatant exposure, and RNA expression. A transcriptomic signature was derived in unstimulated cells to predict the ex vivo endotoxin response. The signature was tested in a separate cohort of 191 septic patients to evaluate for association with clinical outcome. Plasma biomarkers were quantified to measure in vivo host inflammation.
RESULTS: Ex vivo response to endotoxin varied and was unrelated to immunosuppression, white blood cell count, or the causative pathogen. Thirty-five percent of patients demonstrated a minimal response to endotoxin, suggesting early immunosuppression. High ex vivo cytokine production by stimulated blood cells correlated with increased in vitro pulmonary endothelial cell permeability and was associated with attenuated in vivo host inflammation. A four-gene signature of endotoxin response detectable without the need for a functional assay was identified. When tested in a separate cohort of septic patients, its expression was inversely associated with hospital mortality.
CONCLUSIONS: An attenuated ex vivo endotoxin response in early sepsis is associated with greater host in vivo inflammation and a worse clinical outcome.
Copyright © 2022 by the Shock Society.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35066510      PMCID: PMC9246838          DOI: 10.1097/SHK.0000000000001915

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.533


  43 in total

Review 1.  Innate immune sensing and its roots: the story of endotoxin.

Authors:  Bruce Beutler; Ernst Th Rietschel
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

Review 2.  Endotoxins and other sepsis triggers.

Authors:  Steven M Opal
Journal:  Contrib Nephrol       Date:  2010-06-01       Impact factor: 1.580

Review 3.  Endotoxin tolerance: new mechanisms, molecules and clinical significance.

Authors:  Subhra K Biswas; Eduardo Lopez-Collazo
Journal:  Trends Immunol       Date:  2009-09-24       Impact factor: 16.687

4.  Immunosuppression in patients who die of sepsis and multiple organ failure.

Authors:  Jonathan S Boomer; Kathleen To; Kathy C Chang; Osamu Takasu; Dale F Osborne; Andrew H Walton; Traci L Bricker; Stephen D Jarman; Daniel Kreisel; Alexander S Krupnick; Anil Srivastava; Paul E Swanson; Jonathan M Green; Richard S Hotchkiss
Journal:  JAMA       Date:  2011-12-21       Impact factor: 56.272

5.  Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia.

Authors:  Katie L Burnham; Emma E Davenport; Jayachandran Radhakrishnan; Peter Humburg; Anthony C Gordon; Paula Hutton; Eduardo Svoren-Jabalera; Christopher Garrard; Adrian V S Hill; Charles J Hinds; Julian C Knight
Journal:  Am J Respir Crit Care Med       Date:  2017-08-01       Impact factor: 21.405

6.  Stimulated Whole Blood Cytokine Release as a Biomarker of Immunosuppression in the Critically Ill: The Need for a Standardized Methodology.

Authors:  Elisabetta Segre; James N Fullerton
Journal:  Shock       Date:  2016-05       Impact factor: 3.454

Review 7.  Heterogeneity in sepsis: new biological evidence with clinical applications.

Authors:  Aleksandra Leligdowicz; Michael A Matthay
Journal:  Crit Care       Date:  2019-03-09       Impact factor: 9.097

8.  Hydrocortisone treatment is associated with a longer duration of MODS in pediatric patients with severe sepsis and immunoparalysis.

Authors:  Katherine E Bline; Melissa Moore-Clingenpeel; Josey Hensley; Lisa Steele; Kristin Greathouse; Larissa Anglim; Lisa Hanson-Huber; Jyotsna Nateri; Jennifer A Muszynski; Octavio Ramilo; Mark W Hall
Journal:  Crit Care       Date:  2020-09-04       Impact factor: 9.097

9.  Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence.

Authors:  John C Marshall; Paul M Walker; Debra M Foster; David Harris; Melanie Ribeiro; Jeff Paice; Alexander D Romaschin; Anastasia N Derzko
Journal:  Crit Care       Date:  2002-05-02       Impact factor: 9.097

10.  Deciphering heterogeneity of septic shock patients using immune functional assays: a proof of concept study.

Authors:  Chloé Albert Vega; Guy Oriol; François Bartolo; Jonathan Lopez; Alexandre Pachot; Thomas Rimmelé; Fabienne Venet; Véronique Leray; Guillaume Monneret; Benjamin Delwarde; Karen Brengel-Pesce; Julien Textoris; François Mallet; Sophie Trouillet-Assant
Journal:  Sci Rep       Date:  2020-09-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.